Verve Therapeutics Inc (VERV)
6.10
-0.32
(-4.98%)
USD |
NASDAQ |
May 07, 14:43
Verve Therapeutics Research and Development Expense (Quarterly): 46.81M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 46.81M |
| September 30, 2023 | 43.76M |
| June 30, 2023 | 47.26M |
| March 31, 2023 | 47.11M |
| December 31, 2022 | 37.28M |
| September 30, 2022 | 35.20M |
| June 30, 2022 | 33.12M |
| March 31, 2022 | 24.49M |
| Date | Value |
|---|---|
| December 31, 2021 | 25.94M |
| September 30, 2021 | 17.50M |
| June 30, 2021 | 13.42M |
| March 31, 2021 | 11.34M |
| December 31, 2020 | 15.58M |
| September 30, 2020 | 7.618M |
| June 30, 2020 | 5.654M |
| March 31, 2020 | 6.523M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.654M
Minimum
Jun 2020
47.26M
Maximum
Jun 2023
26.16M
Average
25.21M
Median
Research and Development Expense (Quarterly) Benchmarks
| Acorda Therapeutics Inc | 1.009M |
| Eli Lilly and Co | 2.523B |
| Beam Therapeutics Inc | 140.08M |
| Intellia Therapeutics Inc | 108.98M |
| Gritstone Bio Inc | 32.94M |